Table 1 Patient characteristics of the study population
From: Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Characteristic | Percentage (%)/Median (range) | |
|---|---|---|
Age (years) | 61.6 | (26–82) |
Baseline CA-125 level (U/mL) | 582 | (5–24260) |
Nadir CA-125 level (U/mL) | 10 | (3–35) |
Histology | ||
Serous | 67 | (69.8) |
Endometrioid | 10 | (10.4) |
Clear cell | 8 | (8.3) |
Mucinous | 4 | (4.2) |
Transitional | 3 | (3.1) |
Undifferentiated | 3 | (3.1) |
Malignant mixed müllerian tumor | 1 | (1.0) |
Grade | ||
Low | 13 | (13.5) |
High | 83 | (86.5) |
Surgical residual | ||
<1 cm | 62 | (64.6) |
1–2 cm | 3 | (3.1) |
>2 cm | 17 | (17.7) |
Unknown | 14 | (14.6) |
FIGO stage | ||
I | 9 | (9.4) |
II | 8 | (8.3) |
III | 63 | (65.6) |
IV | 14 | (14.6) |
Unknown | 2 | (2.1) |
Neo-adjuvant chemotherapy | 68 | (70.6) |
Paclitaxel-based | 82 | (85.4) |